Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour

Journal of Psychopharmacology

Volumn 23, Issue 2, 2009, Pages 177-189

  Dahan, L ^a   Husum, H ^b   Mnie Filali, O ^a   Arnt, J ^b   Hertel, P ^b   Haddjeri, N ^a  

^a UNIVERSITÉ LYON 1   (France)

^b H LUNDBECK A S   (Denmark)

Author keywords

Antipsychotics; Aripiprazole; Bifeprunox; Dopamine receptors; Dorsal raphe; Schizophrenia; Serotonin receptors; Ventral tegmental area

Indexed keywords

APOMORPHINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIFEPRUNOX; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; ANXIOLYTIC AGENT; BENZOXAZOLE DERIVATIVE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE; SEROTONIN 1A RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DORSAL RAPHE NUCLEUS; DRUG INHIBITION; DRUG RECEPTOR BINDING; FOOTSHOCK; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; TRANQUILIZING ACTIVITY; VENTRAL TEGMENTUM; ANIMAL; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ELECTRIC SHOCK; METABOLISM; NERVE CELL; PHYSIOLOGY; RAPHE NUCLEUS; SPRAGUE DAWLEY RAT; ULTRASOUND; VOCALIZATION;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BENZOXAZOLES; DOPAMINE; ELECTROSHOCK; HALOPERIDOL; MALE; NEURONS; PIPERAZINES; PYRIDINES; QUINOLONES; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; SEROTONIN; ULTRASONICS; VENTRAL TEGMENTAL AREA; VOCALIZATION, ANIMAL;

EID: 62149121073     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108089586     Document Type: Article

References (77)

1. Aghajanian GK, (1978) Feedback regulation of central monoaminergic neurons: evidence from single cell recording studies. Essays Neurochem Neuropharmacol 3: 1 - 32.
2. Arborelius L, Chergui K, Murase S, Nomikos GG, Hook BB, Chouvet G, Hacksell U, Svensson TH, (1993a) The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol 347: 353 - 362.
3. Arborelius L, Nomikos GG, Hacksell U, Svensson TH, (1993b) (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol Scand 148: 465 - 466.
4. Arnt J, Bogeso KP, Christensen AV, Hyttel J, Larsen JJ, Svendsen O, (1983) Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers. Psychopharmacology 81: 199 - 207.
5. Arnt J, Skarsfeldt T, (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18: 63 - 101.
6. Assie MB, Ravailhe V, Faucillon V, Newman-Tancredi A, (2005) Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 315: 265 - 272.
7. Bantick RA, Deakin JF, Grasby PM, (2001) The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15: 37 - 46.
8. Barbato LM, Potkin SG, Heisterberg GJ, Yeung PP, Shapira NA, (2006) A randomised, double-blind, placebo-controlled study of bifeprunox, a partial dopamine D2 receptor agonist, in patients with acute exacerbations of schizophrenia. Neuropsychopharmacology 31: 134.
9. Bardin L, Kleven MS, Barret-Grevoz C, Depoortere R, Newman-Tancredi A, (2006) Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology 31: 1869 - 1879.
10. Bartoszyk GD, (1997) Anxiolytic effects of dopamine receptor ligands: I. Involvement of dopamine autoreceptors. Life Sci 62: 649 - 663.
11. Benkert O, Muller-Siecheneder F, Wetzel H, (1995) Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol 5: 43 - 53.
12. Biala G, (1998) Antidepressant-like properties of some serotonin receptor ligands and calcium channel antagonists measured with the forced swimming test in mice. Pol J Pharmacol 50: 117 - 124.
13. Blier P, de Montigny C, (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15: 220 - 226.
14. Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F, (2007) In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology 191: 745 - 758.
15. Bourin M, Debelle M, Heisterberg J, Josiassen MK, Ostergard JB, Barbata LM, Yeung PP, (2006) Long-term efficacy and safety of bifeprunox in patients with schizophrenia: a 6-month, placebo-controlled study. Neuropsychopharmacology 31: 131.
16. Bunney BS, Aghajanian GK, (1977) d-Amphetamine-induced inhibition of central dopaminergic neurons: direct effect or mediated by a striatonigral feedback pathway? Adv Biochem Psychopharmacol 16: 577 - 582.
17. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB, (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302: 381 - 389.
18. Casey D, Barbato LM, Heisterberg J, Yeung PP, Shapira NA, (2006) Efficacy and safety of bifeprunox in the treatment of patients with acute exacerbations of schizophrenia: results of a dose-finding study. Neuropsychopharmacology 31: 123.
19. Chiodo LA, Bunney BS, (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3: 1607 - 1619.
20. Chojnacka-Wojcik E, Tatarczynska E, Golembiowska K, Przegalinski E, (1991) Involvement of 5-HT1A receptors in the antidepressant-like activity of gepirone in the forced swimming test in rats. Neuropharmacology 30: 711 - 717.
21. Cosi C, Carilla-Durand E, Assie MB, Ormiere AM, Maraval M, Leduc N, Newman-Tancredi A, (2006) Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol 535: 135 - 144.
22. Cryan JF, Leonard BE, (2000) 5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response. Hum Psychopharmacol 15: 113 - 135.
23. Cubeddu LX, Lovenberg TW, Hoffman IS, Talmaciu RK, (1989) Phorbol esters and D2-dopamine receptors. J Pharmacol Exp Ther 251: 687 - 693.
24. Dahan L, Astier B, Vautrelle N, Urbain N, Kocsis B, Chouvet G, (2007) Prominent burst firing of dopaminergic neurons in the ventral tegmental area during paradoxical sleep. Neuropsychopharmacology 32: 1232 - 1241.
25. Del Arco A, Mora F, (2005) Glutamate-dopamine in vivo interaction in the prefrontal cortex modulates the release of dopamine and acetylcholine in the nucleus accumbens of the awake rat. J Neural Transm 112: 97 - 109.
26. Depoortere R, Auclair AL, Bardin L, Bruins Slot L, Kleven MS, Colpaert F, Vacher B, Newman-Tancredi A, (2007) F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms. Br J Pharmacol 151: 266 - 277.
27. Diaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F, (2005) Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 25: 10831 - 10843.
28. Di Giovanni G, Di Mascio M, Di Matteo V, Esposito E, (1998) Effects of acute and repeated administration of amisulpride, a dopamine D2/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons. J Pharmacol Exp Ther 287: 51 - 57.
29. Fa M, Mereu G, Ghiglieri V, Meloni A, Salis P, Gessa GL, (2003) Electrophysiological and pharmacological characteristics of nigral dopaminergic neurons in the conscious, head-restrained rat. Synapse 48: 1 - 9.
30. Floresco SB, West AR, Ash B, Moore H, Grace AA, (2003) Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci 6: 968 - 973.
31. Gonon FG, (1988) Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 24: 19 - 28.
32. Grace AA, (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41: 1 - 24.
33. Grace AA, Bunney BS, (1983) Intracellular and extracellular electrophysiology of nigral dopaminergic neurons-1. Identification and characterization. Neuroscience 10: 301 - 315.
34. Grace AA, Bunney BS, Moore H, Todd CL, (1997) Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci 20: 31 - 37.
35. Haddjeri N, Blier P, de Montigny C, (1998) Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci 18: 10150 - 10156.
36. Hand TH, Hu XT, Wang RY, (1987) Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. Brain Res 415: 257 - 269.
37. Hertel P, Nomikos GG, Iurlo M, Svensson TH, (1996) Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology 124: 74 - 86.
38. Hesselink H, McCreary AC, Glennon JC, Herremans AHJ, Marquis K, Hertel P, Arnt J, Didriksen M, Long SK, (2005) Bifeprunox: a novel partial agonist for the D2 receptor with antagonistic capabilities depending on dopaminergic tone. Eur Neuropsychopharmacol 15: S486.
39. Ichikawa J; ,Ishii H; ,Bonaccorso S; ,Fowler WL; ,. O'Laughlin, IA, Meltzer, HY (2001) 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76: 1521-1531.
40. Jolas T, Schreiber R, Laporte AM, Chastanet M, De Vry J, Glaser T, Adrien J, Hamon M, (1995) Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat. J Pharmacol Exp Ther 272: 920 - 929.
41. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA, (2004) In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 483: 45 - 53.
42. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S, (1995) 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)- quinolinone (OPC-14597). a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274: 329 - 336.
43. Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A, (2005) Mechanism of action of antipsychotic drugs: From dopamine D2 receptor antagonism to glutamate facilitation. Clin Ther 27: S16 - S24.
44. Lejeune F, Millan MJ, (1998) Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535. Synapse 30: 172 - 180.
45. Li Z, Ichikawa J, Dai J, Meltzer HY, (2004) Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 493: 75 - 83.
46. Malberg JE, Eisch AJ, Nestler EJ, Duman RS, (2000) Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20: 9104 - 9110.
47. Marquis KL, Hertel P, Reinders JH, van der Neut M, Ronken E, McCreary AC, Herremans AHJ, Hesselink MB, (2005a) Bifeprunox: a novel atypical antipsychotic sharing dopamine D(2,3,4) receptor and serotonin 5-HT(1A) receptor affinities. Eur Neuropsychopharmacol 15: S487.
48. Marquis KL, Hertel P, Reindeers JH, van der Neut M, Ronken E, Hesselink MB, (2005b) Bifeprunox: a novel atypical antipsychotic sharing dopamine D2 receptor partial agonism and serotonin 5-HT1A receptor agonism. Schizophr Bull 31: 305.
49. Melkersson KI, Dahl ML, Hulting AL, (2004) Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology 175: 1 - 6.
50. Meltzer HY, Matsubara S, Lee JC, (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251: 238 - 246.
51. Meltzer HY, Li Z, Kaneda Y, Ichikawa J, (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27: 1159 - 1172.
52. Millan MJ, (2000) Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther 295: 853 - 861.
53. Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet JM, Cussac D, Nicolas JP, Muller O, Lavielle G, (1998) S 16924 ((R)-2-[1-[2-(2,3- dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)- ethanone). a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J Pharmacol Exp Ther 286: 1341 - 1355.
54. Momiyama T, Amano T, Todo N, Sasa M, (1996) Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area. Eur J Pharmacol 310: 1 - 8.
55. Moore H, West AR, Grace AA, (1999) The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia. Biol Psychiatry 46: 40 - 55.
56. Naber D, Lambert M, (2004) Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry 28: 1213 - 1219.
57. Newman-Tancredi A, Assie MB, Leduc N, Ormiere AM, Danty N, Cosi C, (2005) Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 8: 341 - 356.
58. Newman-Tancredi A, Cussac D, Depoortre R, (2007) Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs 8: 593 - 554.
59. Paxinos G, Watson C, (1998) The Rat Brain in Stereotaxic Coordinates, fourth ed. New York: Academic Press.
60. Rapaport M, Barbato LM, Heisterberg J, Yeung PP, Shapira NA, (2006) Efficacy and safety of bifeprunox versus placebo in the treatment of patients with acute exacerbations of schizophrenia. Neuropsychopharmacology 31: 122.
61. Remy SM, Schreiber R, Dalmus M, De Vry J, (1996) Somatodendritic 5-HT1A receptors are critically involved in the anxiolytic effect of 8-OH-DPAT. Psychopharmacology 125: 89 - 91.
62. Reynolds G, (2004) Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 18: 340 - 345.
63. Rollema H, Lu Y, Schmidt AW, Zorn SH, (1997) Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 338: R3 - R5.
64. Roth BL, Sheffler DJ, Kroeze WK, (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3: 353 - 359.
65. Sales G, Pye D, (1974) Ultrasonic Communication by Animals. London: Chapman and Hall.
66. Snchez C, (2003) Stress-induced vocalisation in adult animals. A valid model of anxiety? Eur J Pharmacol 463: 133 - 143.
67. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R, (2003) Requirement of hippocampal neurogenesis for the behavioural effects of antidepressants. Science 301: 805 - 809.
68. Santiago M, Machado A, Cano J, (1993) Regulation of prefrontal cortical dopamine release by dopamine receptor agonists and antagonists. Eur J Pharmacol 239: 83 - 91.
69. Schreiber R, De Vry J, (1993) Neuronal circuits involved in the anxiolytic effects of the 5-HT1A receptor agonists 8-OH-DPAT ipsapirone and buspirone in the rat. Eur J Pharmacol 249: 341 - 351.
70. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R, (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology Neuropsychopharmacology 228: 1400 - 1411.
71. Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C, Jayathilake K, Meltzer HY, (2001) Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158: 1722 - 1725.
72. Tamminga CA, Carlsson A, (2002) Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 1: 141 - 147.
73. Ungless MA, Magill PJ, Bolam JP, (2004) Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli. Science 303: 2040 - 2042.
74. Venton BJ, Zhang H, Garris PA, Phillips PE, Sulzer D, Wightman RM, (2003) Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing. J Neurochem 87: 1284 - 1295.
75. White FJ, Wang RY, (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221: 1054 - 1057.
76. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB, (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 154: 782 - 791.
77. Zocchi A, Fabbri D, Heidbreder CA, (2005) Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci Lett 387: 157 - 161.